http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience
Aaron Wu,Solomon A. Graf,Nicholas Burwick,Jonathan E. Grim,Zhao Ming Dong,Robert E. Richard,Thomas R. Chauncey 대한혈액학회 2020 Blood Research Vol.55 No.1
BackgroundAutologous stem cell transplantation (autoSCT) can extend remission of mantle cell lym-phoma (MCL), but the management of subsequent relapse is challenging.MethodsWe examined consecutive patients with MCL who underwent autoSCT at Veterans Affairs Puget Sound Health Care System between 2009 and 2017 (N=37).ResultsTen patients experienced disease progression after autoSCT and were included in this analysis. Median progression free survival after autoSCT was 1.8 years (range, 0.3‒7.1) and median overall survival after progression was only 0.7 years (range, 0.1 to not reached). The 3 patients who survived more than 1 year after progression were treated with ibrutinib.ConclusionOur findings suggest that ibrutinib can achieve relatively prolonged control of MCL pro-gressing after autoSCT.